LOPE beats revenue estimates with 6.7% YoY growth; AI integration boosts outlook. Valuation steady.
SFM lifts profit outlook, sees 4.5-6.5% sales growth. Buybacks boost returns, but comps dip.
BC beats Q1 revenue & EPS estimates, but Q2 guidance disappoints. Buy or sell?
JLL beats revenue/EPS estimates, but macro risks loom. AI boosts productivity, yet Asia Pacific contracts weigh.
MA beats Q1 earnings, revenue up 15.8%. Geopolitics pressure cross-border, but value-added services grow 18%.
ILMN beats revenue/EPS estimates, lifts guidance. Clinical demand & NovaSeq X drive growth. Buy?
Ube prices surge 38% amid supply chain strain & 20% export growth. Farmers face rising costs, impacting returns.
Sponsored
Must Read